| Author | Alonso-Padilla, Julio | |
| Author | Abril, Marcelo | |
| Author | Alarcón de Noya, Belkisyolé | |
| Author | Almeida, Igor C. | |
| Author | Angheben, Andrea | |
| Author | Araujo Jorge, Tania | |
| Author | Chatelain, Eric | |
| Author | Esteva, Monica | |
| Author | Gascón, Joaquim | |
| Author | Grijalva, Mario J. | |
| Author | Guhl, Felipe | |
| Author | Hasslocher-Moreno, Alejandro Marcel | |
| Author | López, Manuel Carlos | |
| Author | Luquetti, Alejandro | |
| Author | Noya, Oscar | |
| Author | Pinazo, María Jesús | |
| Author | Ramsey, Janine M. | |
| Author | Ribeiro, Isabela | |
| Author | Ruiz, Andres Mariano | |
| Author | Schijman, Alejandro G. | |
| Author | Sosa-Estani, Sergio | |
| Author | Thomas, M. C. | |
| Author | Torrico, Faustino | |
| Author | Zrein, Maan | |
| Author | Picado, Albert | |
| Access date | 2020-06-04T22:28:15Z | |
| Available date | 2020-06-04T22:28:15Z | |
| Document date | 2020 | |
| Citation | ALONSO-PADILLA, Julio et al. Target Product Profile for a Test for the Early Assessment of Treatment Efficacy in Chagas Disease Patients: An Expert Consensus. PLoS Neglected Tropical Diseases, v. 14, n. 4, p. 1-10, 2020. | pt_BR |
| ISSN | 1935-2727 | pt_BR |
| URI | https://www.arca.fiocruz.br/handle/icict/41546 | |
| Language | eng | pt_BR |
| Publisher | Public Library of Science | pt_BR |
| Rights | open access | |
| Title | Target product profile for a test for the early assessment of treatment efficacy in Chagas disease patients: An expert consensus | pt_BR |
| Type | Article | |
| DOI | 10.1371/journal.pntd.0008035 | |
| Abstract | Six to 7 million people are estimated to be infected by Trypanosoma cruzi, the parasite causing Chagas disease. However, only a small fraction of patients are properly diagnosed and treated. Benznidazole (BNZ) and nifurtimox (NFX) are the first-line antiparasitic treatments currently available, both with long administration regimens (60 days) that can produce adverse side effects. Despite the fact they are not 100% effective in patients with chronic disease, they are the only drugs currently registered, and the benefits of their administration have been confirmed in several clinical studies. Currently, clinical trials with new compounds, using alternative regimens that aim to maintain efficacy whilst reducing toxicity, are ongoing and could lead to new therapeutic opportunities and/or policy change. In any case, the absence of a test for the early assessment of treatment efficacy, often called a test of cure (ToC), is a major obstacle to Chagas disease control. Accurately monitoring treatment response would undoubtedly improve patient management and support the conduct of clinical trials. Although treatment efficacy and treatment response may be conceptually different, we are using these terms synonymously for the purpose of the current target product profile (TPP). | pt_BR |
| Affilliation | Barcelona Institute for Global Health. Hospital Clínic-University of Barcelona. Barcelona, Spain. | pt_BR |
| Affilliation | Fundación Mundo Sano. Buenos Aires, Argentina. | pt_BR |
| Affilliation | Universidad Central de Venezuela. Instituto de Medicina Tropical. Caracas, Venezuela. | pt_BR |
| Affilliation | University of Texas at El Paso. Department of Biological Sciences. Border Biomedical Research Center. El Paso, Texas, United States of America. | pt_BR |
| Affilliation | IRCCS Sacro Cuore Don Calabria Hospital. Department of Infectious-Tropical Diseases and Microbiology. Negrar di Valpolicella, Verona, Italy. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Drugs for Neglected Diseases Initiative. Geneva, Switzerland. | pt_BR |
| Affilliation | Ministerio de Salud. Instituto Nacional de Parasitología "Dr. Mario Fatala Chaben". ANLIS "Dr. Carlos G. Malbrán". Buenos Aires, Argentina. | pt_BR |
| Affilliation | Barcelona Institute for Global Health. Hospital Clínic-University of Barcelona. Barcelona, Spain. | pt_BR |
| Affilliation | Pontificia Universidad Católica del Ecuador. Centro de Investigación para la Salud en América Latina. Quito, Ecuador / Ohio University. Biomedical Sciences Department. Infectious and Tropical Disease Institute. Athens, Ohio, United States of America. | pt_BR |
| Affilliation | Universidad de los Andes. Centro de Investigaciones en Microbiología y Parasitología Tropical. Bogotá, Colombia. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Consejo Superior de Investigaciones Científicas. Instituto de Parasitología y Biomedicina López Neyra. Granada, Spain. | pt_BR |
| Affilliation | Universidade Federal de Goiás. Hospital das Clínicas. Goiania, Brasil. | pt_BR |
| Affilliation | Universidad Central de Venezuela. Instituto de Medicina Tropical. Caracas, Venezuela. | pt_BR |
| Affilliation | Barcelona Institute for Global Health. Hospital Clínic-University of Barcelona. Barcelona, Spain. | pt_BR |
| Affilliation | Instituto Nacional de Salud Pública/CRISP. Tapachula, Chiapas, Mexico. | pt_BR |
| Affilliation | Drugs for Neglected Diseases Initiative. Geneva, Switzerland. | pt_BR |
| Affilliation | Ministerio de Salud. Instituto Nacional de Parasitología "Dr. Mario Fatala Chaben". ANLIS "Dr. Carlos G. Malbrán". Buenos Aires, Argentina. | pt_BR |
| Affilliation | Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular. Buenos Aires, Argentina. | pt_BR |
| Affilliation | Drugs for Neglected Disease initiative Latin America. Rio de Janeiro, RJ, Brasil / CONICET. Epidemiology and Public Health Research Center. Buenos Aires, Argentina. | pt_BR |
| Affilliation | Consejo Superior de Investigaciones Científicas. Instituto de Parasitología y Biomedicina López Neyra. Granada, Spain. | pt_BR |
| Affilliation | Fundación CEADES / Universidad Mayor de San Simón. Cochabamba, Bolivia. | pt_BR |
| Affilliation | Infynity Biomarkers. Lyon, France. | pt_BR |
| Affilliation | Foundation for Innovative Diagnostics. Geneva, Switzerland. | pt_BR |
| Subject | Chagas disease | pt_BR |
| Subject | Parasitic diseases | pt_BR |
| Subject | Trypanosoma cruzi | pt_BR |
| Subject | Diagnostic medicine | pt_BR |
| Subject | Biomarkers | pt_BR |
| Subject | Drug screening | pt_BR |
| Subject | Serology | pt_BR |
| Subject | Treatment guidelines | pt_BR |
| Embargo date | 2020-11-01 | |
